Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52.
Josef S SmolenPhilip MeaseHasan TahirHendrik Schulze-KoopsInmaculada de la TorreLingnan LiMaja HojnikChristophe SapinMasato OkadaRoberto CaporaliJordi GratacósPhilippe GoupilleSoyi Liu LeageSreekumar PillaiPeter NashPublished in: Annals of the rheumatic diseases (2020)
NCT03151551.
Keyphrases
- open label
- rheumatoid arthritis
- clinical trial
- study protocol
- phase ii
- placebo controlled
- double blind
- phase iii
- phase ii study
- randomized controlled trial
- juvenile idiopathic arthritis
- rheumatoid arthritis patients
- disease activity
- cross sectional
- drug induced
- emergency department
- squamous cell carcinoma
- adverse drug
- rectal cancer
- electronic health record